Skip to main content
. 2016 Jun 15;24(3):157–161. doi: 10.1136/ejhpharm-2016-000913

Table 3.

Similarity and non-similarity factors for suspensions

Suspension Commercial tablets f2 f1
St4 Lipovast 68.5 0.4
Lipitor 65.66 2.15
Sp4 Lipovast 56 13
Lipitor 52 9.6